Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1039 • ACR Convergence 2025
CAR-T Therapy in Rheumatoid Arthritis: A Health Systems Analysis of Cost and Global Equity
Asrith Reddy Gandu¹ and Kolluri Prathyusha², ¹Davao medical school foundation, Hyderabad, India, ²University of delaware, Newark, DE
Background/Purpose: Refractory rheumatoid arthritis (RA) affects 30–40% of patients with limited therapeutic options and high disability burdens. Although CAR‑T therapy has been transformative in oncology…
Abstract Number: 0980 • ACR Convergence 2025
Expansion of Viral-Reactive CD8+ T cell Repertoire Stratified by Pathotype in New-onset ACPA+ Rheumatoid Arthritis
Carl Coyle¹, Wittaya Suwakulsiri², Lukas Andriessen³, Megan Soon⁴, Pascale Wehr⁵, Sumera Qureshi⁶, Christopher Altmann⁷, Annabelle Small⁸, Vincent Wong⁹, Andrew Cope⁶, Kevin Wei¹⁰, Hendrik Nel⁵, Mihir Wechalekar¹¹ and Ranjeny Thomas², ¹Kings College London, London, United Kingdom, ²Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ³Frazer Institute, University of Queensland, Woolloongabba, Queensland, Australia, ⁴Frazer Institute, The University of Queensland, Brisbane, Australia, ⁵University of Queensland, Woolloongabba, Queensland, Australia, ⁶King's College London, London, United Kingdom, ⁷Flinders University, Adelaide, Australia, ⁸Flinders University, Bedford Park, South Australia, Australia, ⁹College of Medicine and Public Health, Bedford Park, South Australia, Australia, ¹⁰Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ¹¹Flinders Medical Centre, Adelaide, Australia
Background/Purpose: Development of Rheumatoid Arthritis (RA) is strongly associated with specific HLA-DRB1 genotypes and the HLA-DR antigen binding groove, the shared epitope. HLA-B*08 also increases…
Abstract Number: 0871 • ACR Convergence 2025
The gut microbiome shapes MTX pharmacology and is linked to treatment outcomes
Vanya Sofia Villa Soto¹, Diego Orellana², Erin Reilly³, Chloe Heath², Alexandra Degraeve², Mohana Mukherjee², darren Dumlao², Rebecca Blank⁴, steven Yu², Noah Perlmutter², Judith Ashouri², Jose Scher⁵, andrew Patterson³, Peter Turnbaugh² and Renuka Nayak⁶, ¹University of California, San Francisco, San Francics, CA, ²University of California, San Francisco, San Francisco, CA, ³Pennsylvania State University, University Park, PA, ⁴NYU Langone Health, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶University of California, San Francisco (UCSF), San Francisco, CA
Background/Purpose: Despite advances in targeted therapeutics, methotrexate (MTX) remains the first-line therapy in the treatment of rheumatoid arthritis (RA) and other inflammatory arthritides. However, more…
Abstract Number: 0799 • ACR Convergence 2025
Citrullination of neutrophil serine proteases enhances proteolytic activity, stability and autoantigenicity in Rheumatoid Arthritis
Mario Navarrete Lagos, Ramiza Zaman, Jun Kim, Jeba Atkia Maisha, Hani El-Gabalawy and Liam O'Neil, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: In Rheumatoid Arthritis (RA), autoantibodies develop against endogenous proteins containing the amino acid citrulline, which results from a post-translational modification of arginine catalyzed by…
Abstract Number: 0497 • ACR Convergence 2025
Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)
Nariaki Hao and Naoki Kondo, Division of Orthopedic Surgery, Niigata University Medical and Dental General Hospital, Niigata, Japan
Background/Purpose: To retrospectively evaluate drug survival and reasons for discontinuation of eight biological disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) patients using the Niigata…
Abstract Number: 0480 • ACR Convergence 2025
Efficacy and safety of tacrolimus and its serum concentration in patients with rheumatoid arthritis with inadequate response to methotrexate
Chan-Bum Choi, Hanyang University Hosptial for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Addition of a biologic disease-modifying antirheumatic drug (bDMARD) or targeted synthetic DMARD (tsDMARD) is recommended in patients with rheumatoid arthritis (RA) with inadequate response…
Abstract Number: 0463 • ACR Convergence 2025
Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis
Solana Cushing¹, Susan Goodman², Michael Parides¹, Hadeel Abdul-Rehman¹, Daniel Ramirez², Edward DiCarlo², Kristine Carandang³, Renee Davis⁴, Rebecca Blank⁵, Laura Donlin¹, Anna Helena Jonsson⁶, Amit Lakhanpal², Bella Mehta⁷, Dana Orange⁸ and Melanie smith², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, ⁴New York, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶University of Colorado School of Medicine, Aurora, CO, ⁷Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ, ⁸The Rockefeller University, New York, NY
Background/Purpose: Synovial tissue pathotype may indicate treatment response in RA, but synovial biopsies are not widely available. Synovial fluid (SF) is a promising surrogate. We…
Abstract Number: 0447 • ACR Convergence 2025
Foot-pressure distribution method for detection of foot joint arthritis in patients with rheumatic diseases
Hayagrivas Manicka Bharathkumar¹, Emani Srinija Reddy¹, Bhaskar Pandey², Suryansh Saini¹, Sangeet Rathi¹, Saransh Verma¹, Chinmay Prakash Swami², Deepak Joshi² and Ranjan Gupta¹, ¹All India Institute of Medical Sciences (AIIMS), New Delhi, Delhi, Delhi, India, ²Indian Institute of Technology (IIT), Delhi, Delhi, Delhi, India
Background/Purpose: Rheumatoid arthritis (RA) and Seronegative Spondyloarthritis (SSA), the most common types of inflammatory arthritis, have significant ankle and foot joint involvement. However, these joints…
Abstract Number: 0380 • ACR Convergence 2025
Multidimensional Health Assessment Questionnaire (MDHAQ)/RAPID3, is an Useful Tool to Assess Comorbid and Residual Fatigue in Rheumatoid Arthritis Patients
Rosa Maria Morlà Novell¹, Beatriz Frade Sosa², Maria López-Lasanta³, Meritxell Sallés Lizarzáburu⁴, Noemí Busquets Pérez⁵, Georgina Salvador Alarcón⁶, Marta Valls Roc⁷, Virginia Ruiz-Esquide⁸, Lola Tobalina Mastre⁹, Raimon Sanmartí⁸ and José Gomez-Puerta¹⁰, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ³Hospital Universitari Vall d´Hebron, Barcelona, Spain, ⁴Xarxa Sanitària Althaia Manresa, Manresa, Spain, ⁵Hospital de Granollers, Granollers, Spain, ⁶Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁷Hospital Universitari Dr Trueta, Girona, Sudan, ⁸Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁹IDIBAPS. Hospital Clinic de Barcelona, Barcelona, ¹⁰Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Fatigue is a highly prevalent (40%-70%)1 comorbidity in rheumatoid arthritis (RA) patients, and residual fatigue has been described in a significant proportion of patients…
Abstract Number: 0219 • ACR Convergence 2025
Increased Engagement With the RISE Registry Clinician Dashboard Is Associated With Improving Performance on Some but Not All Rheumatology Quality Measures
Jing Li¹, Jessica Fitzpatrick², Jinoos Yazdany² and gabriela Schmajuk³, ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Previous studies have shown that quality measure performance tends to improve after practices join the ACR’s Rheumatology Informatics System for Effectiveness (RISE) registry, but…
Abstract Number: 0149 • ACR Convergence 2025
Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis
Viengneesee Thao, Molly Moore Jeffery, Nafisseh Warner and Elena myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) have a 2-fold increase in risk for osteoporosis compared to the general population. About 30-50% of RA patients experience…
Abstract Number: 0082 • ACR Convergence 2025
IBI3011, a Humanized anti-IL1RAP Monoclonal Antibody, Inhibits IL1, IL33, IL36-driven Inflammation Pathway, and Attenuates Inflammation in Preclinical Inflammatory Disease Model
Hongling Tian, Lidan Liang, Chenjuan Zhu, Bin Li, Lei Cao, Meng Ni, Fan Chen, Zhimin Zhang, Min Wu, Tong Liu, Jinyang Li, Yao Xiong, Li Li, Shuaixiang Zhou, Enhong Zhong and Huizhong Xiong, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Interleukin 1 receptor accessory protein (IL1RAP) serves as a co-receptor that forms receptor complexes with IL1R1, ST2, and IL36R and mediates signaling pathways triggered…
Abstract Number: 0064 • ACR Convergence 2025
Sclerostin from marrow adipogenic precursors is essential for bone and joint homeostasis in mice
Tailin He and Yifang Mei, Shenzhen Third People's Hospital, Shenzhen, China (People's Republic)
Background/Purpose: A novel mesenchymal subpopulation known as 'marrow adipogenic lineage precursors' (MALPs) has been identified, characterized by the expression of various adipocyte markers while lacking…
Abstract Number: 0006 • ACR Convergence 2025
QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
Jenny McGovern, Georgios Eleftheriadis, Thomas Grothier, Eva Bugallo Blanco, Anna Koi, Mahsa Nemani, Cameron Allum, Emily Hurley, Daniela Penston, Marc Martinez-Llordella, Luke Devey and Nathalie Belmonte, Quell Therapeutics, London, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) are immune mediated inflammatory diseases (IMID) where a complex interplay of tissue and immune cell activation drives…
Abstract Number: 2628 • ACR Convergence 2025
Calprotectin and Anti-CCP Antibodies Predict Development of Preeclampsia
Daniele Marcy¹, Nanette Santoro², Claudia Lugo³, Kristin Sturm² and Kristen Demoruelle⁴, ¹University of Colorado, Northglenn, CO, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of Colorado, Denver, CO, ⁴University of Colorado Anschutz Medical Campus, Golden, CO
Background/Purpose: Several systemic autoimmune diseases are associated with an increased risk of preeclampsia. Preeclampsia is a pregnancy complication characterized by new-onset hypertension after 20 weeks…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].